United States - English - NLM (National Library of Medicine)

avkare, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg

United States - English - NLM (National Library of Medicine)

golden state medical supply - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niacin extended-release tablet usp is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. - niacin extended-release tablet usp in combination with a bile ac

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1. niacin extended-release tablets are indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2. in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 3. in patients with a history of coronary artery disease (cad) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. 4. niacin extended-release tablets in combination with a bile aci

United States - English - NLM (National Library of Medicine)

redmont pharmaceuticals, llc - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - i. therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia (types iia and iib)† , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the ncep treatment guidelines6 ). prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, hdl cholesterol, and triglycerides. ii. nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (types iv and v hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. such patients typically have serum triglyceride levels over 2,000 mg/dl and have elevations of vldl cholesterol as well as fasting chylomicrons (type v hyperlipidemia)† . subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dl are unlikely to develop pancreatitis. therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dl who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. some type iv patients with triglycerides under 1,000 mg/dl may, through dietary or alcoholic indiscretion, convert to a type v pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. drug therapy is not indicated for patients with type i hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of vldl. inspection of plasma refrigerated for 14 hours is helpful in distinguishing types i, iv, and v hyperlipoproteinemia7 . nicotinic acid is contraindicated in patients with a known hypersensitivity to any component of this medication; significant or unexplained hepatic dysfunction; active peptic ulcer disease; or arterial bleeding.

United States - English - NLM (National Library of Medicine)

emerald therapeutics, llc - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - i. therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia (types iia and iib)† , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the ncep treatment guidelines6 ). prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, hdl cholesterol, and triglycerides. ii. nicotinic acid is

United States - English - NLM (National Library of Medicine)

redmont pharmaceuticals, llc - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - i. therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia (types iia and iib)†, when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the ncep treatment guidelines6 ). prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, hdl cholesterol, and triglycerides. ii. nicotinic acid is

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niacin extended-release tablets are indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. - niacin extended-release tablets in

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a), lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - niacin 500 mg - therapy with lipid-altering agents should be only one component of multiple risk-factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also table 8 and the ncep treatment guidelines1 ). advicor (niacin extended-release and lovastatin) is indicated for use when treatment with both niaspan and lovastatin is appropriate. as described in the labeling for niaspan and lovastatin below, the components of advicor are both indicated for the treatment of hypercholesterolemia. patients receiving treatment with advicor should be on a standard cholesterol-lowering diet and should continue on this diet during treatment. niaspan is indicated as an adjunct to diet for reduction of elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with pr

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia,

United States - English - NLM (National Library of Medicine)

rebel distributors corp - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 1000 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia, n